Holy Name Hospital in Teaneck, New Jersey Acquires Daxor BVA-100 Blood Volume Analyzer

Business Wire, Sept 27, 2004

NEW YORK -- Daxor Corporation, (AMEX: DXR), a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from the Nuclear Medicine Department at Holy Name Hospital in Teaneck, New Jersey. Holy Name Hospital is a fully accredited, not-for-profit community hospital located in suburban Teaneck, New Jersey. Founded and sponsored by the Sisters of St. Joseph of Peace in 1925, the hospital has grown to become a comprehensive 361-bed medical center offering the most modern medical technology coupled with an enduring tradition of compassion and respect. Affiliation with New York Presbyterian Healthcare System further brings the advantages of large urban hospitals to the community, with access to clinical trials and expanded education for its physicians.

Dr. Jacqueline Brunetti, Medical Director, Department of Radiology, said, "We are very pleased to offer this technology to our physicians here at Holy Name. The BVA-100 will provide a 98 % accurate measurement of a patient's blood volume status necessary to better diagnose and treat patients with congestive heart failure, hypertension and syncope. We also plan to incorporate blood volume measurement into our dialysis program to monitor a patient's blood volume prior to treatment, minimizing complications." Holy Name Hospital is one of the first community hospitals in the United States to offer this important test to their patients.

Dr. Joseph Feldschuh, a cardiologist and President of Daxor Corporation, noted that at the just concluded annual meeting of the American Society of Heart Failure Symposium in Toronto, the statistics from multiple sources reported a death rate of 30% to 40% within 1 year of initial hospitalization of congestive heart failure patients. A report in the American Journal of Cardiology (May 2004) in congestive heart failure patients followed for 2 years at the affiliated Columbia Presbyterian Medical Center reported a 55% death rate after 2 years in patients who had hypervolemia (too much blood) as compared to a 0% death rate for patients with a normal blood volume. This remarkable study provides strong evidence that appropriate treatment which results in normalization of a patient's blood volume can significantly improve life expectancy. The study also documented that experienced cardiology trained physicians were only correct 51% of the time when they attempted to evaluate the patient's blood volume status by physical examination and other common tests. The Daxor BVA-100 blood volume analyzer was used in these studies.

For more information about the BVA-100 and other Daxor products and services can be found at www.daxor.com.